News

Pharmaxis announced that Bronchitol (mannitol) has been approved in Russia for the treatment of both pediatric and adult patients with cystic fibrosis (CF), the largest market to date for the medication with this indication. Bronchitol is also approved to treat pediatric and adult CF patients (older than age 6) in Australia, and…

Toxins produced by mold found on nuts and corn can exacerbate cystic fibrosis (CF) and pave the way for airway infections, as they block self-protective mechanisms for the lungs. The study, “Fungal Aflatoxins Reduce Respiratory Mucosal Ciliary Function,” published in the journal Scientific Reports, showed that the toxins…

Proteostasis Therapeutics announced it will present preliminary data from its ongoing Phase 1 clinical trial evaluating ascending doses of PTI-428, an oral treatment for people with cystic fibrosis (CF). The data will be presented at the 30th Annual North American Cystic Fibrosis Conference (NACFC 2016), taking place Oct. 27–29 in Orlando, Florida.

Certain molecules present in the sputum — “coughed-up” material from the trachea and lungs — can help to predict the onset of an inflammation attack in patients with cystic fibrosis (CF), a new study by researchers at the University of California reported. The study, “Metabolomics Of Pulmonary Exacerbations Reveals The Personalized Nature Of…

Penn State researchers developed a fluorescent sensor able to easily and accurately detect salt concentrations in the sweat or other bodily fluids. Based on citric acid molecules, the sensor is highly sensitive and selective for chloride, the main diagnostic marker for cystic fibrosis (CF), and may enable rapid and low-cost…

The Boomer Esiason Foundation (BEF) announced that its cystic fibrosis (CF) ambassador, Jerry Cahill, has joined with Emily Schaller, a CF patient inspired by Cahill to start running and cycling in 2007, in the BEF’s 3rd Annual Bike to Breathe event, running now through Sept. 26. The two are riding 600 miles…

Corbus Pharmaceuticals announced that its CEO will give an update on clinical work and anticipated milestones for Resunab (JBT-101), the company’s synthetic oral drug designed to resolve chronic inflammation and fibrosis, at the upcoming Jefferies Cystic Fibrosis Summit. The treatment is under evaluation in three Phase 2 clinical trials. Last year, Corbus received…

Two studies published in the Journal of Clinical Investigation (JCI) demonstrate the potential of pigs with cystic fibrosis (CF) — the ExeGen CFTR miniswine model — to test the effectiveness and workings of gene therapies for the disease. This animal research model was developed by Exemplar Genetics, a subsidiary…

Corbus Pharmaceuticals Holdings recently announced the completion of patient enrollment in its Phase 2 clinical trial assessing Resunab for the treatment of cystic fibrosis (CF). Resunab is a first-in-class, synthetic oral endocannabinoid-mimetic drug that binds to the CB2 receptor present on activated immune cells and fibroblasts, helping resolve inflammation and halting…

A research team has developed a new way of specifically and efficiently identifying bacterial infections caused by the Burkholderia cepacia complex (BCC) in patients with cystic fibrosis (CF). This complex is among the most prevalent of bacterial infections detected in CF patients — who are known to be prone to chronic or recurrent lung…